Alovudine F-18

Generic Name: Alovudine F-18

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃FN_₂O_₄

CAS Number: 287114-80-1

Unique Ingredient Identifier: 2X1K91UT6N

Background: Alovudine F-18 is under investigation in clinical trial NCT02819024 (Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

Phase 2

Completed

Conditions: Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Procedure: CT
Drug: 18F-FLT
Procedure: PET

First Posted Date: 2007-12-13

Last Posted Date: 2016-12-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00572728

Locations: 🇺🇸
Morton Plant Hospital, Clearwater, Florida, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 24 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy